Skip to main content
Michigan OPEN

Emerging Drug Trends in Michigan

Virtual
Jan 13, 2026

12:00 – 1:00pm

Click Here or Scan the QR Code to Register!

Join us for an insightful webinar exploring the latest emerging drug trends in Michigan, where we’ll delve into current patterns affecting communities across the state. We’ll explore the significant implications these trends have on public health and safety throughout the state. Additionally, we will discuss how these trends are affecting public health, safety, and community well-being, while exploring effective strategies for prevention and intervention.

Learning Objectives:

  • Discuss the latest emerging drug trends in Michigan, including specific substances and usage patterns affecting various communities.
  • Examine how these drug trends are impacting public health and safety in Michigan.
  • Outline available resources and support systems for addressing substance use issues.

1 CE Credit (1.0 hour):

  • CME
  • MCBAP
  • Social Work
  • Meets DEA Training Requirements

Accreditation Statement:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of MyMichigan Health and OPEN: Overdose Prevention Engagement Network. MyMichigan Health is accredited by the Michigan State Medical Society (MSMS) to provide continuing medical education for physicians. MyMichigan Health designates this live activity for a maximum of 1 AMA PRA Category Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Presenter(s):

  • Elaine Dougherty

Event Disclosures:

Elaine Dougherty has no financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients to disclose.

Planners and other Administrative Support:

Katrina Hernandez, MS has no financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients to disclose.”